Research programme: beta 3 adrenoreceptor agonists - sanofi-aventis

Drug Profile

Research programme: beta 3 adrenoreceptor agonists - sanofi-aventis

Alternative Names: SAR-150640

Latest Information Update: 18 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Preterm labour

Most Recent Events

  • 31 Aug 2007 Preclinical data added to the pharmacokinetics and Women's health pharmacodynamics sections
  • 28 Feb 2007 Preclinical trials in Preterm labour in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top